Health Advisory May 27, 2014



Pertussis Increase Continues

Janet Berreman, MD, MPH Health Officer

Please distribute to all providers in your practice

Current Situation and Update

- More than 1700 cases of pertussis have been reported to the California Department of Public Health since January 2014. This is more than a threefold increase compared to the same period in 2013.
- In Berkeley, there have been more than 20 cases of pertussis reported since January.
 This is a 5-fold increase compared to last year at this time. Berkeley cases range from
 infants to teenagers, with most being 10 -17 years of age. Cases have involved at least
 two schools in the Berkeley Unified School District.
- Infants too young to be fully immunized remain most vulnerable to severe and fatal
 pertussis. Statewide, most of the 77 hospitalized cases to date have been in children 3
 months of age or younger. Two pertussis deaths, the first reported in California since
 2010, occurred in infants. There have been no pertussis hospitalizations or deaths
 reported in Berkeley.
- Statewide, over 90% of reported pertussis cases have been in children younger than 18 years of age, with 32% being 14 through 16 years of age. Outbreaks of pertussis in elementary, middle, and high schools have been reported throughout the state.
- Immunity from acellular pertussis vaccine wanes more quickly than immunity from the
 previous whole-cell vaccine. (Whole-cell vaccines were removed from the U.S. childhood
 vaccine series in 1997.) Data suggest that the State is entering another cyclical peak of
 pertussis, similar to that of 2010.

Recommendations for Clinicians: Vaccinate

- Immunize all women, irrespective of their immunization history, with Tdap during every pregnancy between 27-36 weeks' gestation to optimize antibody transfer and protection of infants at birth. This is the most important measure to help protect young infants against pertussis. Tdap during pregnancy has not been found to be associated with an increased risk of adverse events in vaccinated women or their infants. Immunization of pregnant women with Tdap is covered by insurers, including Medi-Cal.
 - Postpartum vaccination does not provide transplacental antibodies to newborns but may prevent maternal acquisition and transmission of pertussis. If the postpartum mother has never received Tdap, promptly administer Tdap before discharge home.
- Advise women during pregnancy and delivery that other adults in contact with the newborn, such as fathers, grandparents, older siblings, and babysitters, should also be upto-date with their Tdap vaccine.
- Immunize young infants promptly with DTaP. During a community outbreak, the first dose
 of DTaP can be given as early as 6 weeks of age, especially to infants whose mothers did
 not receive Tdap during pregnancy. The primary DTaP vaccine series reduces severe



Pertussis Increase Continues

Health Advisory May 27, 2014

> Janet Berreman, MD, MPH Health Officer

Department of Health Services Public Health Division (510) 981-5300

Please distribute to all providers in your practice

disease in young infants, and even the first dose may offer some protection against fatal disease.

Encourage all persons to be up-to-date with <u>current pertussis vaccination</u>
 <u>recommendations.</u> As part of the "cocooning" strategy, all close contacts of infants (e.g., parents, siblings, grandparents, child care providers, etc.) and all <u>healthcare personnel</u> should be immunized against pertussis, particularly those who work with infants or pregnant women.

Test and treat

- <u>Diagnosing pertussis</u> in <u>young infants</u> is challenging, as they may have little or no cough, whoop, or fever. Mild illness may quickly progress to respiratory distress, apnea, cyanosis, or seizures. Delays in treatment may increase the risk of a fatal outcome. A white blood cell count of ≥20,000 cells/mm³ with ≥50% lymphocytes is a strong indication of pertussis.
- Consider pertussis even in recently vaccinated people when evaluating patients with symptoms compatible with pertussis. Immunity after immunization wanes within a few years.
- Consider pertussis **regardless of age** in patients with persistent cough. Symptoms are generally milder in teens and adults, especially in those who have received Tdap. Adults may report sweating episodes or feeling as if they're choking.
- For <u>testing</u> by PCR or culture, obtain a nasal aspirate (preferable) or nasopharyngeal swab. Serologic testing for pertussis is not recommended.
- Report all suspected pertussis cases to City of Berkeley Public Health Communicable Disease Program. Please fax Confidential Morbidity Reports to 510-981-5345.
- Initiate antibiotic <u>treatment</u> **prior to obtaining test results**, especially in infants and pregnant women or those who are in close contact with them. Azithromycin is preferred because of efficacy and compliance.
- Instruct patients with pertussis to stay home from school or daycare until they have received 5 days of antibiotics, and to avoid contact with infants and pregnant women.
- Provide <u>antibiotic prophylaxis</u> to household contacts, caregivers, and other persons who
 have had direct contact with respiratory, oral, or nasal secretions and aerosols from a
 symptomatic case, especially when there is an infant or pregnant woman in the home. The
 dosage and duration for antibiotic prophylaxis is the same as treatment and should not be
 shortened.

Resources and Educational Materials

- California Department of Public Health pertussis website: http://www.cdph.ca.gov/HealthInfo/discond/Pages/Pertussis.aspx
- Center for Disease Control and Prevention pertussis webpage for clinicians: http://www.cdc.gov/pertussis/clinical/index.html
- **REPORTING information:** City of Berkeley Public Health Division: http://www.ci.berkeley.ca.us/Health Human Services/Public Health/Communicable Disease Reporting.aspx